High-Dose Transarterial Radioembolization of Hepatic Metastases Using Yttrium-90 Resin Microspheres
Authors:
- Charlotte C. I. SchneiderCSCharlotte C. I. Schneider
- Belinda J. de Wit-Van der VeenBVBelinda J. de Wit-Van der Veen
- Sanne M. A. JansenSJSanne M. A. Jansen
- Kenneth F. M. HergaardenKHKenneth F. M. Hergaarden
- Margot E. T. TesselaarMTMargot E. T. Tesselaar
- Niels F. M. KokNKNiels F. M. Kok
- Larissa W. van GolenLGLarissa W. van Golen
- Arthur J. A. T. BraatABArthur J. A. T. Braat
- Regina G. H. Beets-TanRBRegina G. H. Beets-Tan
- Tarik R. BaetensTBTarik R. Baetens
- Elisabeth G. KlompenhouwerEKElisabeth G. Klompenhouwer
Open Access
Abstract
Background/Objectives: Over the past few years, high-dose radioembolization (≥150 Gy) has become widely adopted for the treatment of primary liver cancer, while evidence for its application in hepatic metastases is still limited. The aim of this study was to evaluate the safety and efficacy of high-dose transarterial radioembolization (TARE) in patients with hepatic metastases using resin Yttrium-90 (90Y) microspheres. Methods: In this retrospective analysis, patients who were treated with high-dose TARE for hepatic metastases with 90Y resin microspheres between May 2019 and April 2025 were included. The primary outcomes were treatment efficacy and toxicity assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Treatment efficacy was evaluated based on radiological response according to Response Evaluation Criteria in Solid Tumors version 1.1, time to progression and overall survival (OS). Secondary outcomes included 90Y PET/CT post-treatment voxel-based local deposition model dosimetry and its relations to response. Results: A total of 15 patients were included, with hepatic metastases originating from colorectal cancer (n = 11, 73.3%), neuroendocrine tumor (n = 3, 20%) and breast cancer (n = 1, 6.7%). Seven patients (47.7%) had undergone one or multiple prior loco(regional) liver treatments and 13 (86.7%) patients had prior systemic therapy. The median mean tumor absorbed dose was 160.7 Gy (IQR 127.6–245.0 Gy), and the median normal liver parenchyma dose was 40.3 Gy (IQR 21.7–52.3 Gy). Disease control was achieved in all patients, with partial response in 10 patients (66.7%) and stable disease in 5 patients (33.3%) after 3 months. The median OS was 26.5 months (95% CI 24.5 months to no estimate). Two patients (13.3%) experienced grade 3 laboratory toxicity. No grade 4 or 5 toxicities were observed. Conclusions: High-dose TARE with 90Y resin microspheres resulted in a high disease control rate and demonstrated a favorable safety profile, even in this heavily pretreated cohort.Keywords
This publication has 29 references indexed in Scilit:
- Histopathologic outcomes of hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 resin microspheresEuropean Journal of Nuclear Medicine and Molecular Imaging, 2025
- Utility of pre-procedural [99mTc]TcMAA SPECT/CT Multicompartment Dosimetry for Treatment Planning of 90Y Glass microspheres in patients with Hepatocellular Carcinoma: comparison of anatomic versus [99mTc]TcMAA-based SegmentationEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT StudyCardioVascular and Interventional Radiology, 2023
- Optimizing 90Y Particle Density Improves Outcomes After RadioembolizationCardioVascular and Interventional Radiology, 2022
- EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compoundsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY StudyHepatology, 2021
- Radiation segmentectomy of hepatic metastases with Y-90 glass microspheresAbdominal Radiology, 2021
- Yttrium‐90 radiation segmentectomy for hepatic metastases: A multi‐institutional study of safety and efficacyJournal of Surgical Oncology, 2020
- Comparative dosimetry between 99mTc-MAA SPECT/CT and 90Y PET/CT in primary and metastatic liver tumorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteriaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012